Full-year financial results for 2011
Q1 2012 Consolidated turnover

- ***A growth strategy focused on orphan oncology products***
- ***Promising products in advanced development***
- ***Reinforced cash reserves at €28.7 million as of December 31, 2011***

Paris, April 17, 2012 – BioAlliance Pharma SA (Euronext Paris-BIO), a Company dedicated to orphan oncology products and specialty products, today announced its consolidated turnover for the fiscal year ending December 31, 2011.

« 2011 represents a cornerstone in builing up our growth strategy in the orphan oncology product area. We have received the green light from the French health authorities for phase III trial with Livatag®, enlarged enrolment of patients in the phase II trial with clonidine Lauriad™, and obtained positive preliminary phase I results with our AMEP® biotherapy. These achievements contribute to building a strong position for our Company in the orphan oncology product area, where a high sales potential and a major medical need exist", declares Judith Greciet, CEO of BioAlliance Pharma. "*Moreover, the ongoing international deployment of Loramyc®, notably with an agreement signed for Japan, and the submission of a European registration dossier for Sitavir®/Sitavig® are particularly key milestones that reinforce the value of our second product portfolio".*

Analysis of 2011 consolidated results

BioAlliance Pharma consolidated results are strongly determined by non recurring revenues, representative of scheduled payments from international licence agreements signed by the Company:

- In 2011, the non recurring turnover amounted to €1.5 million, notably thanks to a milestone payment from Therabel and the signature of the licence agreement with Sosei for Japan.
- *In 2010, the payment received following the US registration of Oravig® and the signature of a European licence agreement for Loramyc® had generated an exceptionally high non recurring turnover (€20.2 million)*.

Summarized profit & loss account for 2011:

In thousands €	31/12/2011	31/12/2010
Recurring revenues from licence agreements	1 365	1 388
Non recurring revenues from licence agreements	1 451	20 257
Other revenues	415	887
Total revenues	**3 231**	**22 532**
Total operating expenses	**(18 169)**	**(19 976)**
Operating profit / (loss)	**(14 938)**	**2 592**
Financial profit / (loss)	**316**	**217**
Net profit / (loss)	**(14 622)**	**2 809**

While actively conducting its clinical and industrial development programs (Livatag®, clonidine Lauriad™, AMEP® and Sitavir®), the Company has optimized its operating expenses (-9% as compared with 2010) and contained its research and development investments which total €7.9 million for the full-year 2011. The Company is also eligible for a €1.1 million research tax credit and has requested its reimbursement at the beginning of 2012.

The Company's available cash reserves amounted to €28.7 million as of December 31, 2011, an increase on the previous year's closing figure of €20.9 million. It notably includes paiements received from Therabel end of December for a total amount of €3.5 millions.

Perspectives for 2012

"Our growth is primarily based on the development of our products, with a focus on the highly promising orphan oncology portfolio. Nevertheless, it is necessary to reinforce this portfolio with other projects or platforms that would enable us to enlarge the pipeline, to spread risks inherent to drug development and thus to create additional value for our shareholders", declares Judith Greciet, CEO of BioAlliance Pharma.

The Company is planning following growth catalysts in 2012:

- The active start of patient recruitment of in the phase III trial with Livatag® (doxorubicin Transdrug™) in the primary liver cancer;
- The acceleration of the phase II trial with clonidine Lauriad™ through an international expansion in the prevention of radio/chemotherapy-induced oral mucositis in patients with head and neck cancer;
- The start of a phase I/II trial (intramuscular administration) with Amep® biotherapy in metastatic melanoma;
- The receivability of Sitavir®/Sitavig® registration application for the US, enabling its evaluation to be initiated, as well as the continuation of the European registration procedure started end of 2011;
- The signature of new international licence agreements with adequate partners, especially for the Company's most advanced products.

Q1 2012 consolidated turnover

BioAlliance Pharma's consolidated turnover for Q1 2012 amounted to €290,000. The consolidated cash reserves stood at €22.8 million as of March 31, 2012, after payment of a €1.5 million tax for Sitavir®/Sitavig® US registration application. An additional €1 million non conditional payment from Therabel is expected by December 31, 2012.

"2012 is an important year as regards strategic progress and valuation of our projects. The Company's financial status gives us today a good visibility, enabling us to pursue actively our planned developments", added Nicolas Fellmann, CFO of BioAlliance Pharma.

Analyst meeting and audio/web-conference (in English)

BioAlliance Pharma will hold a meeting at 9 am on April 18, 2012, at its corporate headquarters (49 boulevard Martial Valin, Paris,France). An audio/web-conference in English will be organized at 11:30 am Paris time (GMT+1). Access numbers and codes are given below.

1) Audio connexion from France or abroad: **+33 (0)1 70 77 09 35**

2) Webconference connexion: **https://www.anywhereconference.com**

3) Login: **135276545**

4) Participant Code: **775532**

For conference call replay: +**33(0)1 72 00 15 00** (in English)

Conference reference: **276545#**

The 2011 financial statements were approved by the Board of Directors on April 17, 2012. The Statutory Auditors have completed their audit and are in the process of issuing their report.

About BioAlliance Pharma
Dedicated to cancer and supportive care treatment with a focus on resistance targeting and orphan products, BioAlliance conceives and develops innovative products, for specialty markets especially in the hospital setting and for orphan or rare diseases.
Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs. The company's teams have the key competencies required to identify, develop and register drugs in Europe and the USA.

BioAlliance Pharma has developed an advanced product portfolio:
Specialty products
Loramyc®/Oravig® (oropharyngeal candidiasis in immunocompromised patients): Registered in 28 countries (EU, US, Korea)
Sitavir® (Acyclovir Lauriad™) (labialis herpes): Positive phase III final results; registration status
Fentanyl Lauriad™ (chronic cancer pain): Positive preliminary Phase I results

Orphan Oncology products
Livatag® (Doxorubicin Transdrug™) in primary) liver cancer: Authorization for Phase III clinical trial
Clonidine Lauriad™ (mucositis): Phase II on going
AMEP™ (invasive melanoma): Phase I on going
For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com

Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2010 Reference Document filed with the AMF on April 7, 2011, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).

BioAlliance Pharma SA
Judith Greciet, CEO
Tel +33 1 45 58 76 00
judith.greciet@bioalliancepharma.com
Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71 00
nicolas.fellmann@bioalliancepharma.com

ALIZE RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59
caroline@alizerp.com